


09-13-04

Express Mail Label No. EU169119492US

Date of Deposit: September 10, 2004

Attorney Docket No. CST-201 CIP

12W



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS: Rush *et al.*

ASSIGNEE: Cell Signaling Technology, Inc.

SERIAL NUMBER: 10/777,893

EXAMINER: Not Yet Assigned

FILING DATE: February 12, 2004

ART UNIT: 1646

FOR: IMMUNOAFFINITY ISOLATION OF MODIFIED PEPTIDES FROM  
COMPLEX MIXTURES

September 10, 2004

Beverly, Massachusetts

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Attached hereto for filing in the above-identified patent application are the following:

- ☒ Transmittal Letter (w/duplicate) (2 pages);
- ☒ Supplemental Information Disclosure Statement (2 pages);
- ☒ IDS Form – PTO 1449 (w/duplicate) (2 pages);
- ☒ References CX (29 pages) and CY (4 pages) (2 references);
- ☒ Return Postcard.

Respectfully submitted,

James Gregory Cullem, Reg. No. 43,569  
Intellectual Property Counsel  
CELL SIGNALING TECHNOLOGY, INC.  
166B Cummings Center  
Beverly, Massachusetts 01915  
Tel: (978) 867-2311  
Fax: (978) 867-2400

Express Mail Label No.: EU169119492US

Date of Deposit: September 10, 2004

Attorney Docket No. CST-201 CIP

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

APPLICANTS:

Rush *et al*

ASSIGNEE:

CELL SIGNALING TECHNOLOGY, INC.

SERIAL NUMBER: 10/777,893

EXAMINER: Not yet assigned

FILING DATE: February 12, 2004

ART UNIT: 1646

FOR:

IMMUNOAFFINITY ISOLATION OF MODIFIED PEPTIDES FROM  
COMPLEX MIXTURES

September 10, 2004

Beverly, Massachusetts

Mail Stop Amendment

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, Applicants hereby make of record the documents listed below and on the attached modified Form PTO-1449 (submitted in duplicate) in the above-identified application. The order of presentation of the references should not be construed as an indication of the importance of the references.

**U.S. Patent or Application Documents:**

**Foreign Patent Documents:**

**Other Prior Art – Non Patent Literature Documents:**

Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
Novagen Technical Bulletin, "pET System Manual", 9 <sup>th</sup> Edition, May 2000
Hoffman, et al., Journal of Immuno. Methods, 112: pp. 113-120 (1988)

This Information Disclosure Statement is being filed:

- ☐ within three months of the filing date of the National Application;
- ☐ within three months of the filing date of the entry of the National Stage, as set forth in 37 C.F.R. §1.491, in an International Application; or
- ☒ before the mailing date of a first Office Action on the merits in the above-identified case.

Accordingly, no fee or certification is required. 37 C.F.R. §1.97.

A copy of each of the above-identified information is enclosed unless otherwise indicated on the attached Form PTO-1449 (modified). These documents were cited in a corresponding Canadian patent application, and are not believed to be relevant. It is respectfully requested that the Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims, and signs the enclosed form PTO-1449 to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application.

By submitting this Information Disclosure Statement, the Applicant makes no representation that: (1) a search has been performed, of the extent of any search performed, or that more relevant information does not exist; (2) the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b); and (3) the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.


Notwithstanding any statements by the Applicant, the Examiner is urged to form his/her own conclusion regarding the relevance of the cited information. An early and favorable action is hereby requested. Please charge any additional fees that may be due, or credit any overpayment of same, to Deposit Account No. 50-1774, Reference No. CST-201 CIP.

Respectfully submitted,



James Gregory Cullem, Reg. No. 43,569  
Intellectual Property Counsel  
CELL SIGNALING TECHNOLOGY, INC.  
166B Cummings Center  
Beverly, MA 01915

Dated: 9/10/04



Modified Form 1449/PTO		Application Number	10/777,893
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		Filing Date	February 12, 2004
		First Named Inventor	Rush <i>et al.</i>
		Group Art Unit	1646
		Examiner Name	Not yet assigned
		Attorney Docket Number	CST-201 CIP

U.S. PATENT DOCUMENTS							
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate

U.S. CO-PENDING PATENT APPLICATIONS							
Exam Initials	Cite No.	U.S. Patent App. Serial No.	Status	Name of Applicant(s) and Assignee	Art Unit	Examiner	Filing Date

FOREIGN PATENT DOCUMENTS							
Exam Initials	Cite No.	Foreign Patent Document Office Number		Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes No	

OTHER NON PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
	CX	Novagen Technical Bulletin, "pET System Manual", 9 <sup>th</sup> Edition, May 2000
	CY	Hoffman, <i>et al.</i> , <i>J. of Immuno. Methods</i> , 112: pp. 113-120 (1988)

\* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, U.S.S.N. 09/535,364 , filed March 24, 2000, U.S.S.N. 09/148,712, filed September 4, 1998 , and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.

Include copy of this form with next communication to applicant.